Relationship of serum levels of VEGF and TGF-β1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4785-4789

  Fu, Zhan Zhao ^a   Gu, Tao ^a   Fu, Bao Hong ^a   Hua, Hai Xia ^a   Yang, Sen ^a   Zhang, Yan Qiu ^a   Gao, Li Ming ^a   Li, Ping ^a  

^a FIRST HOSPITAL OF QINHUANGDAO   (China)

Author keywords

3D CRT; Non small cell lung cancer; Radiosensitivity; TGF 1; VEGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; TGFB1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERIATRIC PATIENT; HUMAN; INOPERABLE CANCER; LINEAR ACCELERATOR; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOSENSITIVITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; TREATMENT RESPONSE; BLOOD; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION TOLERANCE; RADIOTHERAPY, CONFORMAL; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902981134     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1628-3     Document Type: Article

References (28)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801.
2. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148(1-2):259-72.
3. Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, et al. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC cancer. 2010;10:431.
4. Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, et al. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci. 2012;103(5):945-50.
5. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94. (Pubitemid 351720831)
6. Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sanchez Hernandez I, Munoz Molina GM, et al. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest. 2010;28(4):393-8.
7. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4(1):12-21.
8. Rades D, Setter C, Dunst J, Dahl O, Schild SE, Noack F. Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol. 2010;186(6):307-14.
9. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an eastern cooperative oncology group study. Clin Cancer Res. 2008;14(5):1407-12. (Pubitemid 351413922)
10. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4-10. (Pubitemid 41680947)
11. He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, et al. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated pi3k/akt/mtor signaling pathway. Cancer Sci. 2011;102(1):219-25.
12. Hseu YC, Chen SC, Lin WH, Hung DZ, Lin MK, Kuo YH, et al. Toona sinensis (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells. J Ethnopharmacol. 2011;134(1):111-21.
13. Karal-Yilmaz O, Serhatli M, Baysal K, Baysal BM. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly (d, l-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique. J Microencapsul. 2011;28(1):46-54.
14. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23(5):537-48.
15. Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis. 2010;31(6):1080-6.
16. Aihara K, Ikeda Y, Yagi S, Akaike M, Matsumoto T. Transforming growth factor-beta1 as a common target molecule for development of cardiovascular diseases, renal insufficiency, andmetabolic syndrome. Cardiol Res Pract. 2010;2011:175381.
17. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory smads in non-small cell lung cancer. J Thorac Oncol. 2010;5(4):417-9.
18. Zhao L, Wang L, Ji W, Wang X, Zhu X, Hayman JA, et al. Elevation of plasma tgf-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from beijing and Michigan. Int J Radiat Oncol Biol Phys. 2009;74(5):1385-90.
19. Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, Kalemkerian GP, et al. The predictive role of plasma tgf-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer. 2008;59(2):232-9. (Pubitemid 351173403)
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
21. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and BFGF in tumours and blood. Lung Cancer. 2006;51(2):143-58. (Pubitemid 43144358)
22. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91(5):964-71.
23. Naumnik W, Nilklinska W, Ossolinska M, Chyczewska E. Serum levels of hmgb1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol. 2009;47(4):703-9.
24. Kaya A, Çiledag A, Gulbay B E, Baris M. Poyraza, Gokhan Celika, Elif Sen, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004; 98(7): 632-6. (Pubitemid 38949927)
25. Wang Y, Dong QZ, Zhang QF, Li ZX, Wang EH, Qiu XS. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010;101(5):1279-85.
26. Ando S, Nojima K, Ishihara H, Suzuki M, Ando M, Majima H, et al. Induction by carbon-ion irradiation of the expression of vascular endothelial growth factor in lung carcinoma cells. Internati J Radiation Biol. 2000;76(8):1121-7. (Pubitemid 30488621)
27. Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, et al. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and BFGF in non-small-cell lung cancer. Lung Cancer. 2011;73(3):366-74.
28. Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, et al. TGF-beta1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38beta to proapoptotic p38alpha. MCR. 2012;10(5):605-14.